{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:30:55Z","timestamp":1790872255675,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1124\/jpet.122.001423","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T18:25:56Z","timestamp":1670351156000},"page":"382-392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease"],"prefix":"10.1016","volume":"384","author":[{"given":"Glenn A.","family":"Reinhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu Sheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khing Jow","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Gueneva-Boucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehrod B.","family":"Brenneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bosanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Fryer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Sarko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine M.","family":"Boustany-Kari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven S.","family":"Pullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.122.001423_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ndt\/gfu250","article-title":"Renal histologic changes and the outcome in patients with diabetic nephropathy","volume":"30","author":"An","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.122.001423_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.115.230706","article-title":"A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat","volume":"356","author":"Boustany-Kari","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001423_bib3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00210-021-02149-4","article-title":"Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease","volume":"394","author":"B\u00e9nardeau","year":"2021","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.122.001423_bib4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001423_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2350-15-9","article-title":"Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis","volume":"15","author":"Dellamea","year":"2014","journal-title":"BMC Med Genet"},{"key":"10.1124\/jpet.122.001423_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.matbio.2018.02.006","article-title":"Renal fibrosis: Primacy of the proximal tubule","volume":"68\u201369","author":"Gewin","year":"2018","journal-title":"Matrix Biol"},{"key":"10.1124\/jpet.122.001423_bib9","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180111","article-title":"Oxidative stress induces BH4 deficiency in male, but not female, SHR","volume":"38","author":"Gillis","year":"2018","journal-title":"Biosci Rep"},{"key":"10.1124\/jpet.122.001423_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ki.2012.20","article-title":"Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis","volume":"82","author":"Grgic","year":"2012","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.122.001423_bib11","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1021\/acs.jmedchem.0c02154","article-title":"Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)","volume":"64","author":"Hahn","year":"2021","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.122.001423_bib12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/ndt\/gfn716","article-title":"Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes","volume":"24","author":"Hanai","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.122.001423_bib22697287","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ackd.2017.10.011","article-title":"The Global Epidemiology of Diabetes and Kidney Disease","volume":"25","author":"Koye","year":"2018","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/jpet.122.001423_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2337\/dc07-1762","article-title":"Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy","volume":"31","author":"Lajer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.122.001423_bib14","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001423_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.122.001423_bib16","first-page":"456","article-title":"Unilateral obstructive nephropathy in the rabbit. I. Early morphologic, physiologic, and histochemical changes","volume":"28","author":"Nagle","year":"1973","journal-title":"Lab Invest"},{"key":"10.1124\/jpet.122.001423_bib4151149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","article-title":"Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage","volume":"20","author":"Nath","year":"1992","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1124\/jpet.122.001423_bib17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-8993(02)03015-9","article-title":"Regional distribution of protein and activity of the nitric oxide receptor, soluble guanylyl cyclase, in rat brain suggests multiple mechanisms of regulation","volume":"950","author":"Nedvetsky","year":"2002","journal-title":"Brain Res"},{"key":"10.1124\/jpet.122.001423_bib18","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/00365510802187226","article-title":"Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study","volume":"68","author":"Persson","year":"2008","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1124\/jpet.122.001423_bib01979551","doi-asserted-by":"crossref","first-page":"F1160","DOI":"10.1152\/ajprenal.00008.2020","article-title":"UT-A1\/A3 knockout mice show reduced fibrosis following unilateral ureteral obstruction","volume":"318","author":"Rianto","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.122.001423_bib20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO-independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"10.1124\/jpet.122.001423_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/sj.bjp.0704483","article-title":"Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies","volume":"135","author":"Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.122.001423_bib22","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1172\/JCI28371","article-title":"Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels","volume":"116","author":"Stasch","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.122.001423_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/jpet.122.001423_bib24","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1681\/ASN.2015060647","article-title":"Severity and Frequency of Proximal Tubule Injury Determines Renal Prognosis","volume":"27","author":"Takaori","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.122.001423_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.122.001423_bib26","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA Consensus Conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524004142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.122.001423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:28:02Z","timestamp":1739971682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524004142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0022356524004142"],"URL":"https:\/\/doi.org\/10.1124\/jpet.122.001423","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.122.001423","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}